M. M. Javle

453 total citations
20 papers, 230 citations indexed

About

M. M. Javle is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. M. Javle has authored 20 papers receiving a total of 230 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 11 papers in Cancer Research and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. M. Javle's work include Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). M. M. Javle is often cited by papers focused on Pancreatic and Hepatic Oncology Research (11 papers), Cancer Genomics and Diagnostics (7 papers) and Colorectal Cancer Treatments and Studies (5 papers). M. M. Javle collaborates with scholars based in United States, Norway and Belgium. M. M. Javle's co-authors include Rune Smaaland, Jon Arne Søreide, Morten Lapin, Satu Oltedal, Oddmund Nordgård, Kjersti Tjensvoll, Bjørnar Gilje, J. L. Abbruzzese, Robert A. Wolff and Rachna T. Shroff and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

M. M. Javle

19 papers receiving 226 citations

Peers

Countries citing papers authored by M. M. Javle

Since Specialization

Citations

This map shows the geographic impact of M. M. Javle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. M. Javle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. M. Javle more than expected).

Fields of papers citing papers by M. M. Javle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. M. Javle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. M. Javle. The network helps show where M. M. Javle may publish in the future.

Co-authorship network of co-authors of M. M. Javle

This figure shows the co-authorship network connecting the top 25 collaborators of M. M. Javle. A scholar is included among the top collaborators of M. M. Javle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. M. Javle. M. M. Javle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	P-144 Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: phase 3 PROOF trial 2020 ·Annals of Oncology ·Ghassan K. Abou‐Alfa, Ivan Borbath, (unknown), Lipika Goyal, Ángela Lamarca, Teresa Macarulla, Do‐Youn Oh, Sameek Roychowdhury, Saeed Sadeghi, Rachna T. Shroff, Michael F. Howland, (unknown), (unknown), Amit Pande, M. M. Javle	2
2	Clinical relevance of circulating KRAS mutated DNA in plasma from patients with advanced pancreatic cancer 2015 ·Molecular Oncology ·Kjersti Tjensvoll, Morten Lapin, (unknown), Satu Oltedal, (unknown), Bjørnar Gilje, Jon Arne Søreide, M. M. Javle, Oddmund Nordgård, Rune Smaaland	118
3	Abstract 5241: Clinical relevance of circulating tumor DNA in plasma from pancreatic cancer patients 2015 ·Cancer Research ·Kjersti Tjensvoll, Morten Lapin, (unknown), Satu Oltedal, (unknown), Bjørnar Gilje, Jon Arne Søreide, M. M. Javle, Oddmund Nordgård, Rune Smaaland	1
4	Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer. 2011 ·Journal of Clinical Oncology ·M. M. Javle, Gauri R. Varadhachary, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, (unknown), B. Nebiyou Bekele, Siddhartha Kar, Robert A. Wolff, J. L. Abbruzzese	15
5	Comprehensive analysis of potential predictive biomarkers for insulin-like growth factor type-1 receptor (IGF-1R) targeted therapy in pancreatic cancer. 2011 ·Journal of Clinical Oncology ·Rachna T. Shroff, M. M. Javle, (unknown), Robert A. Wolff, David J. Mauro, George N. Naumov, Michael Nebozhyn, (unknown), (unknown), (unknown)	1
6	Role of anticoagulation (AC) in patients with advanced pancreatic cancer (APC) with splanchnic venous thrombosis (SVT). 2011 ·Journal of Clinical Oncology ·Siddhartha Kar, Priya Bhosale, Michael J. Overman, J. Weatherly, Xiao Li, Robert A. Wolff, M. M. Javle	4
7	Phase I/II study of MK-0646, the humanized monoclonal IGF-1R antibody in combination with gemcitabine or gemcitabine plus erlotinib (E) for advanced pancreatic cancer. 2010 ·Journal of Clinical Oncology ·M. M. Javle, Gauri R. Varadhachary, Rachna T. Shroff, Pritam Bhagwan Bhosale, Michael J. Overman, J. Weatherly, Robert A. Wolff, J. L. Abbruzzese	15
8	Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. 2010 ·Journal of Clinical Oncology ·(unknown), Gerald J. Fetterly, M. M. Javle, (unknown), Gregory E. Wilding, Josephia R. Muindi, Marwan Fakih, Nithya Ramnath, Carol Johnson, D L Trump	1
9	Gene expression profile (GEP) for the prediction of pathologic complete response (pCR): Preliminary data from a neoadjuvant study of capecitabine (C), oxaliplatin (OXP), and radiation (RT) for esophageal cancer (EC). 2010 ·Journal of Clinical Oncology ·Nikhil I. Khushalani, Gang Yang, Wen Tan, (unknown), (unknown), Renuka Iyer, Saikrishna S. Yendamuri, Chukwumere Nwogu, Hector Nava, M. M. Javle	1
10	Prognostic significance of xCT gene single nucleotide polymorphisms (SNPs) in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (GEM) plus platinum analogues (PLAT). 2010 ·Journal of Clinical Oncology ·Tony Jun Huang, (unknown), J. Weatherly, (unknown), Peter W. Gout, Robert A. Wolff, J. L. Abbruzzese, M. M. Javle	0
11	Molecular predictors of response to antiangiogenic therapy in HCC: Data from bevacizumab and erlotinib phase II study. 2010 ·Journal of Clinical Oncology ·Ahmed O. Kaseb, Jeffrey S. Morris, (unknown), Michiko Iwasaki, (unknown), M. M. Javle, Elizabeth Garrett‐Mayer, Georgiana Onicescu, J. L. Abbruzzese, (unknown)	1
12	Osteoclastic giant cell tumor of the pancreas: A distinct clinical and pathologic entity. 2010 ·Journal of Clinical Oncology ·Nishin A. Bhadkamkar, M. M. Javle, Robert A. Wolff, William D. Payne, Damien Tan	1
13	Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. 2010 ·Journal of Clinical Oncology ·Nikhil I. Khushalani, Gerald J. Fetterly, Renuka Iyer, Alan Litwin, William E. Brady, M. M. Javle	1
14	Role of surveillance CT scans in resected PC: Correlation with CA19-9 and symptoms. 2010 ·Journal of Clinical Oncology ·(unknown), Jason B. Fleming, Robert A. Wolff, Dean B. Evans, Eric P. Tamm, Christopher H. Crane, M. M. Javle, J. L. Abbruzzese, (unknown), Gauri R. Varadhachary	1
15	Inhibition of mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: The results of two prospective phase II studies 2009 ·Journal of Clinical Oncology ·M. M. Javle, Henry Xiong, Sujan Reddy, Pritam Bhagwan Bhosale, (unknown), Gauri R. Varadhachary, David R. Fogelman, Ahmed S. Kaseb, Robert A. Wolff, J. L. Abbruzzese	7
16	Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC) 2009 ·Journal of Clinical Oncology ·Ahmed O. Kaseb, Michiko Iwasaki, M. M. Javle, Georgiana Onicescu, Elizabeth Garrett‐Mayer, J. L. Abbruzzese, Melanie B. Thomas	15
17	Serum CA 19–9 level as a surrogate marker for prognosis in locally advanced pancreatic cancer (LAPC) 2008 ·Journal of Clinical Oncology ·David R. Fogelman, Priyanka Pathak, Wei Qiao, Romil Chadha, (unknown), Davide Melisi, Robert A. Wolff, J. L. Abbruzzese, M. M. Javle	3
18	Polymorphisms of genes involved in gemcitabine metabolism correlate with prognosis in patients receiving neoadjuvant therapy for pancreatic cancer 2008 ·Journal of Clinical Oncology ·M. M. Javle, Teiji Okazaki, Dean B. Evans, Robert A. Wolff, J. L. Abbruzzese, (unknown)	5
19	Cardiac function after chemoradiation for esophageal cancer: comparison of heart dose-volume histogram parameters to multiple gated acquisition scan changes 2005 ·Diseases of the Esophagus ·(unknown), H Malhotra, M. M. Javle, (unknown), (unknown), S de Boer, Matthew B. Podgorsak, (unknown), (unknown)	27
20	Should preoperative, post-chemoradiotherapy endoscopy be routine for esophageal cancer patients? 2004 ·Diseases of the Esophagus ·Aasma Shaukat, Amir Mortazavi, Todd L. Demmy, (unknown), Neal Wilkinson, Gang Yang, James L. Kepner, M. M. Javle	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact